Letters
Ebola virus vaccines
Ebola vaccines based on adenovirus vectors and risk of HIV
BMJ 2015; 350 doi: https://doi.org/10.1136/bmj.h1307 (Published 10 March 2015) Cite this as: BMJ 2015;350:h1307
- Eric J Kremer, INSERM director of research1,
- Philippe Van de Perre, professor2
- 1Institut de Génétique Moléculaire de Montpellier, Université Montpellier; INSERM U 1058, CHU 34293 Montpelier, France
- 2INSERM U 1058, Pathogenesis and Control of Chronic Infections, University of Montpellier, Montpellier, France
- eric.kremer{at}igmm.cnrs.fr
Under intense pressure to react, WHO is set to fast track phase II-III evaluation of candidate Ebola virus vaccines based on adenovirus vectors in west and central Africa.1
However, adenovirus vectors regularly show encouraging preclinical results but disappointing clinical efficacy. Despite the immunogenicity shown in phase II-III studies, two proof of concept HIV vaccine trials (STEP and Phambili) that used an adenovirus vector …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.